EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 327 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Two Large Studies with New Screening Tests Show Promise for Increasing... March 18, 2024 Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 Record Impact Factor for Annals of Oncology Highlights Growing Influence of... July 2, 2026 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 Load more HOT NEWS Family Brings Joy & Raises Money With Their Extravagant Christmas Light... ScottishPower supports vital research into air pollution and cancer Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical...
